AI can predict patient response to popular Crohn's treatment

Andrea Park - Print  | 

A predictive machine learning model was able to identify how effectively patients with Crohn's disease would respond to long-term usage of ustekinumab, according to a new study in JAMA Network Open.

Researchers from the University of Michigan trained the model using demographic and laboratory data obtained in previous clinical trials. The data described 401 patients with active Crohn's who had been monitored while taking ustekinumab, an immunosuppressive drug, over the course of at least 42 weeks.

Once trained, the model was able to reliably identify how a Crohn's patient who had been given one dose of ustekinumab would react to the treatment in the long term. The technology could therefore be used to predict those patients who may not respond well to biological monotherapy, saving them money and reducing delays in achieving remission.

More articles about AI:
Machine learning tool detects Alzheimer's in brain tissue
Elon Musk's neurotech startup falls short in funding round
FDA clears AI tool to flag pulmonary embolism in CT scans

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.